Mikkel Bring Christensen

Mikkel Bring Christensen

Clinical Professor

Member of:

  • Clinical Pharmacology


Publication year:
All
11 - 13 out of 13Page size: 10
  1. 2023
  2. Published

    Separate and combined effects of long-term GIP and GLP-1 receptor activation in patients with type 2 diabetes: a structured summary of a study protocol for a double-blind, randomised, placebo-controlled clinical trial

    Helsted, M. M., Gasbjerg, Lærke Smidt, Vilsbøll, Tina, Nielsen, C. K., Forman, Julie Lyng, Christensen, Mikkel Bring & Knop, Filip Krag, 2023, In: BMJ Open. 13, 2, 5 p., e065736.

    Research output: Contribution to journal › Journal article › Research › peer-review

  3. Published

    The impact of type 2 diabetes and glycaemic control on mortality and clinical outcomes in hospitalized patients with COVID-19 in the capital region of Denmark

    Kliim-Hansen, V., Johansson, K. S., Gasbjerg, Lærke Smidt, Solem, Espen Victor Jimenez, Petersen, Tonny Studsgaard, Nyeland, M. E., Winther-Jensen, M., Ankarfeldt, Mikkel Zöllner, Pedersen, M. G., Ellegaard, A. M., Knop, Filip Krag & Christensen, Mikkel Bring, 2023, In: Diabetes, Obesity and Metabolism. 26, 1, p. 160-168 9 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  4. Published

    Tirzepatide. Dual GLP-1/GIP receptor agonist, Treatment of type 2 diabetes and obesity

    Jensen, T. L., Brønden, Andreas, Karstoft, Kristian, Sonne, David Peick & Christensen, Mikkel Bring, 2023, In: Drugs of the Future. 48, 3, p. 179-196 18 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

Previous 1 2 Next

ID: 96275756